KymeraTx news and milestones

WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small mole…

Enrollment completed in KT-621 BROADEN2 Phase 2b AD trial with topline data expected by year-end 2026; Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2…

Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026 KT-621 Phase 3 trials in AD…

Dr. Rooney, former immunology leader at Johnson & Johnson, will lead clinical development strategy across Kymera's industry-leading oral immunology portfolio Jared Gollob, MD, wi…

CNBC's

BROADEN2 enrollment completed nearly six months ahead of anticipated timelines KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial on…

Bruce Booth, DPhil, Co-Founder and Chairman, to remain an Independent Director XPJbh5wxnSOqepaFyjY53IPyBK72aKnwFd8X63naB0DdLo=" target="_blank" rel="nofollow"Kymera Therapeutics,…

First-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million milestone payment from Sanofi Xw-V46t3ppW-m0Vg8loC2rrmMOcGpekzm0rXj6c0nkCxRad_A_U="…

Penny Carlson will oversee global clinical development operations across Kymera's oral immunology portfolio Jeremy Chadwick will retire from his role as Chief Operating Officer X…

KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively FDA granted Fast…

The FDA granted fast track designation to KT-621 for treating patients with moderate to severe eosinophilic asthma, according to a press release from Kymera Therapeutics.The rele…

Kymera Therapeutics will announce Q1 2026 financial results on April 30, 2026, with a video conference at 8:30 a.m. ET.Quiver AI SummaryKymera Therapeutics, Inc., a clinical-stag…

Kymera has taken the next step toward its goal of bringing oral drugs with biologics-like activity to autoimmune disease patients with a Phase Ib readout i...

Now, Kymera will aim to show its experimental drug helps patients with eczema and asthma in larger clinical trials.

WATERTOWN, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc.(NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecu…

WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molec…

Kymera has a clear mission: to transform immunology with targeted protein degraders that enable "oral drugs with biologics-like activity," CE...